**WHAT DOES THIS MEAN FOR PATIENTS**? {#sec1a}
=====================================

Hyaluronate (HA) is a naturally occurring substance found throughout the body, which has been used as an additive to the liquid solution in which embryos are transferred into the womb as part of an IVF cycle. There is evidence from clinical studies showing that adding HA to this transfer medium improves live birth rates, and it has been proposed that it helps the embryo attach to the wall of the womb. The most commonly used HA-containing transfer medium is called EmbryoGlue®, in accordance with this proposed mode of action. Such embryo transfer media are widely offered to patients as so-called 'add-ons' to their IVF treatment. However, there have been no direct studies demonstrating that HA acts on the attachment of embryos to the endometrial epithelial cells which line the wall of the womb.

In this study, human embryos donated to research at different stages were shown to have the biological machinery required to respond to HA. The attachment of day 6 embryos to endometrial epithelial cells grown in a dish was carefully assessed, and adding EmbryoGlue® to the solution did not affect attachment when compared with embryos in control transfer medium without EmbryoGlue®. These experiments suggest that HA-containing embryo transfer medium might not directly promote embryo attachment to the womb lining but might improve IVF success rates in a different way, for example by promoting embryo growth. Further research is required in this area.

Introduction {#sec1}
============

Current evidence suggests that the type of commercially available embryo culture media used in ART is not associated with success rates ([@ref37], [@ref62]). However, when used at the point of embryo transfer, there is evidence that media containing high levels of hyaluronate (HA) increase live birth rate per transfer and implantation rate per embryo ([@ref13], [@ref25]). HA is a glycosaminoglycan prevalent in follicular, oviductal and uterine fluid, and the oocyte cumulus extracellular matrix ([@ref42]). HA levels are increase in the endometrial stroma during the secretory phase of the menstrual cycle and fall to very low levels at menstruation ([@ref19], [@ref49]), suggestive of a role in implantation. Thus, HA is considered a physiologically relevant additive to embryo medium with a relatively low risk profile ([@ref30], [@ref14]). However, despite initial data from a mouse model, two decades ago, that showed increased rates of implantation and foetal development in HA-containing embryo transfer medium ([@ref28]), and clinical evidence that has led to a widespread use of HA-containing medium in ART ([@ref13]), the mechanism of action of HA at implantation is not known.

HA has a range of biological functions, including stimulation of cell proliferation, migration and adhesion ([@ref11]), and control of swelling and shape in collagenous extracellular matrices and the pericellular environment ([@ref60]). HA is synthesised as various relative molecular masses (Mr) by synthase enzymes HAS1--3, while hyaluronidases HYAL1--3 cleave high Mr forms of HA into low Mr forms that have trophic signalling properties: receptors CD44, hyaluronan mediated mobility receptor (HMMR) and Toll-like receptor 4 (TLR4) bind HA at the cell surface ([@ref58]). In mouse, the addition of an HAS inhibitor negatively impacts blastocyst formation, and in bovine, the addition of Hyal2 to embryo culture medium improves development in a CD44-dependent manner ([@ref26], [@ref38]). However, little is known of the impacts of the HA system during human preimplantation development, other than the demonstration of *HAS2*, *CD44* and *HMMR* expression in embryos ([@ref17], [@ref21], [@ref26]).

An intriguing hypothesis posits that high Mr HA acts as an embryo attachment 'glue', facilitating the first interaction between blastocyst-stage embryo trophectoderm (TE) and endometrial epithelial cells by bridging between receptors on both surfaces ([@ref28], [@ref13], [@ref4]). Indeed, HA-containing embryo transfer media are sold under commercial trade names (e.g. EmbryoGlue**®**) implying this mode of action. Conversely, such media improve clinical ART success rate regardless of the developmental stage at which embryos are transferred to the uterus ([@ref13]). Embryos transferred at day 3 in the presence of HA are unlikely to benefit from an attachment 'glue' mode of action since attachment is not initiated until 2--3 days later. In support of an alternative hypothesis, bovine data reveal that HA may moderate implantation ([@ref26], [@ref38]). Similarly, we have recently shown that the enzymatic reduction of high Mr HA in endometrial epithelial cell cultures promotes mouse blastocyst attachment in an *in vitro* model of implantation ([@ref9]).

Studying human embryo implantation directly requires the use of *in vitro* models. Interactions between blastocysts and primary human epithelial cells *in vitro* have been previously reported ([@ref35], [@ref34], [@ref7], [@ref27], [@ref40], [@ref44], [@ref32], [@ref33], [@ref8], [@ref12]). However, the 2D culture phenotype of primary endometrial epithelial cells does not recapitulate the *in vivo* epithelium ([@ref16]). Moreover, the kinetics of blastocyst attachment at implantation have not been evaluated in such models. The human endometrial adenocarcinoma Ishikawa cell line ([@ref43]) offers a controlled *in vitro* epithelial system to study human embryo implantation, which is thought to begin on day 6 of embryo development ([@ref31], [@ref1]). Ishikawa cells are moderately polarised ([@ref20], [@ref15]), show a surface composition that resembles endometrial epithelium ([@ref51]) and have proven receptivity to rodent blastocysts ([@ref29], [@ref48]).

In light of the uncertainties surrounding HA activity on human embryos and implantation, we designed a study to investigate the effect of a commercial HA-containing medium (EmbryoGlue®) on human embryo attachment to Ishikawa cells. We find no evidence that HA transfer medium promotes embryo attachment.

Materials and Methods {#sec2}
=====================

Human embryos {#sec3}
-------------

Embryos unsuitable for treatment (based on morphological grade) from current ART cycles (fresh) or surplus to treatment requirements from previous ART cycles (frozen) were obtained with informed written consent from patients at Old St Marys Hospital, Manchester, or other IVF units in the north west of England, in accordance with ethics approval from the NRES committee south central (Berkshire) (REC reference: 12/SC/0649) and a research licence from the Human Fertilisation and Embryology Authority (HFEA; R0026), centre 0067 (Old St Mary's Hospital; fresh embryo research) and the University of Manchester (0175; frozen-thawed embryo research). Embryos frozen at either the pronuclear (PN) or early cleavage stages were thawed using ThawKit Cleave (Vitrolife, Gothenburg, Sweden) according to the manufacturer's instructions. None of the embryos used were from PGT cycles. Embryos were cultured in G1 and G2 sequential media or GTL continuous culture medium (Vitrolife) to day 6 post-fertilisation and graded using a standardised scheme ([@ref22], [@ref5]). Only embryos exhibiting blastocyst morphology on day 6 were used. Artificial hatching was performed by passing blastocysts through three drops of acid Tyrodes buffer, pH 2.5, (Sigma-Aldrich, Poole, UK). Removal of the zona pellucida (ZP) was assessed by microscopy before washing in G2 or GTL medium.

Microarray analysis of oocyte and embryo gene expression {#sec4}
--------------------------------------------------------

The microarray analysis reported here (GeneChip® Human Genome U133 Plus 2.0 Array \[Life Technolgies, Paisley, UK\]) was performed previously ([@ref50], [@ref54]). cDNA samples were obtained from individual human oocyte, 4-cell, 8-cell single blastomeres, intact 8-cell, whole blastocyst, TE and inner cell mass (ICM) samples. The lower threshold of positive relative gene expression was set at 5.64, based on *MAS5* normalisation.

EmbryoGlue® treatment of blastocysts {#sec5}
------------------------------------

EmbryoGlue® (Vitrolife) was used as a high-HA medium, as it contains 0.5 mg/ml HA compared with 0.125 mg/ml HA in G2 embryo culture medium ([@ref24]). We were unable to obtain information from the manufacturer on the Mr profile of HA in EmbryoGlue® or a suitable control medium lacking HA. Day 6 blastocysts were treated with EmbryoGlue® or control medium (GTL) by 10 min incubation (as suggested in the clinical protocol) after hatching. Blastocysts were added directly to Ishikawa cells in a 3-μl treatment medium.

Blastocyst attachment assay {#sec6}
---------------------------

Ishikawa cells (ECACC 99040201) were grown to confluence on glass coverslips in 24-well plates coated with 2% Matrigel (Sigma) in growth medium (1:1 DMEM:Ham's F12, 10% foetal bovine serum, 2-mM l glutamine, 100-ug/ml streptomycin, 100-IU/ml penicillin) (Sigma) at 37°C and in 95% air and 5% CO~2~. Cells were washed and replenished with serum-free growth medium immediately prior to the transfer of single day 6 blastocysts to individual wells and co-culture at 37°C, 95% air and 5% CO~2~. We have previously determined mouse blastocyst attachment stability to Ishikawa cells based on the levels of oscillation upon agitation ([@ref48]), however, the larger size of day 6--8 human blastocysts prevented such grading of attachment stability due to the oscillation of embryos despite visible, substantial areas of attachment ([Fig. 1](#f1){ref-type="fig"}, arrows). Therefore, embryos were scored simply as 'attached' or 'unattached' during co-culture. All co-cultures were fixed at 48 h with 4% formaldehyde for 30 min, at which time attachment was re-classified as 'stably attached' (remaining attached at fixation), 'weakly attached' (detached at fixation) or 'unattached' ([@ref52]).

![**Phase contrast image of a live day 8, human blastocyst attached to Ishikawa cells after 48 h in co-culture.** An area of trophectoderm (TE)-mediated attachment to Ishikawa cells (arrows) is visible. Scale bars 20 μm.](hoz033f1){#f1}

Statistical analysis {#sec7}
--------------------

Attachment rates and embryo grades were analysed using the Chi-squared test. Repeated Chi-squared analysis with a Bonferroni correction for multiple comparisons was used to assess the effect of EmbryoGlue® treatment on embryo attachment at each experimental time point. Statistical significance was set as *P* \< 0.05 and measured using SPSS (IBM, Portsmouth, UK).

![**Gene expression of the hyaluronate (HA) system.** Expression was studied by the microarray analysis of individual human oocytes (n = 4), 4-cell embryos (n = 4), 8-cell stage blastomeres (n = 8 blastomeres from one embryo), intact 8-cell embryos (n = 3), intact blastocysts (n = 4) and isolated ICM and TE samples (n = 6 each), using Mas5 normalisation. Data are mean ±SEM, with the lower threshold of positive relative gene expression set at 5.64 (dotted line), based on *MAS5* normalisation. HA receptor genes *CD44* and *HMMR*, hyaluronan synthase genes *HAS1--3* and hyaluronidase genes *HYAL1--3*.](hoz033f2){#f2}

Results {#sec8}
=======

Expression of HA system components in pre-implantation human embryos {#sec9}
--------------------------------------------------------------------

We screened our existing human pre-implantation embryo transcriptome data ([@ref50], [@ref54]) for the major components of the HA system. HA receptors *CD44* and *HMMR* ([Fig. 2A and B](#f2){ref-type="fig"}), but not *TLR4* (data not shown), were expressed at all stages, including oocyte, 4-cell, 8-cell and blastocyst, and equally in TE compared with ICM. The HA synthase enzymes, *HAS1--3*, were expressed at the above stages, although *HAS2* was weakest at 8-cell and blastocyst stages ([Fig. 2C--E](#f2){ref-type="fig"}). Hyaluronidases *HYAL1--3* were expressed in both ICM and TE, although *HYAL1* was low or absent at earlier stages ([Fig. 2F--H](#f2){ref-type="fig"}). Human blastocyst expression was confirmed by quantitative PCR analysis for two genes selected at random, *HMMR* and *HYAL1* (unpublished data). These data suggest that HA receptors and systems for synthesising and degrading HA are present throughout pre-implantation development.

Hatching status and TE grade predict blastocyst attachment to Ishikawa cells in an *in vitro* model of implantation {#sec10}
-------------------------------------------------------------------------------------------------------------------

In order to examine the effect of HA transfer medium, we first characterised the attachment of day 6 human blastocysts to Ishikawa cells. Co-cultures were monitored after 24 and 48 h; 7/17 (41.2%) blastocysts from current IVF cycles (fresh embryos) had attached to Ishikawa cells after 24-h co-culture. By 48 h, 6/14 (42.9%) were attached: 5/14 (35.7%) weakly and 1/14 (7.1%) stably ([Fig. 3A](#f3){ref-type="fig"}). Frozen embryos were developed to day 6 after thawing at either PN (13/17) or at day 2 (4/17). We observed that 9/17 (52.9%) of these blastocysts were attached to the cells after 24-h co-culture, and at 48 h, 2/15 (13.3%) displayed weak attachment and 8/15 (53.3%) stable attachment ([Fig. 3B](#f3){ref-type="fig"}). Stable attachment rates were higher for frozen compared with fresh embryos (*P* = 0.007).

![**Attachment of day 6 human blastocysts to Ishikawa cells.** (**A**) Day 6 human blastocysts from current IVF cycles (fresh) were co-cultured with Ishikawa cells for 48 h and attachment (attached or not attached) was assessed after 24 h. At 48 h, co-cultures were fixed with paraformaldehyde (PFA) and blastocysts that remained attached after fixation were scored as stably attached, whereas those, which became detached during fixation, were scored as weakly attached. Two co-cultures were fixed after 24 h to assess attachment stage (data not reported here). (**B**) Day 6 human blastocysts developed from frozen embryos were co-cultured with Ishikawa cells for 48 h. Attachment was assessed at 24 h (attached or not attached), and at 48 h, co-cultures were fixed with PFA. Blastocysts that remained attached after fixation were scored as stably attached, whereas those that became detached during fixation were scored as weakly attached. Two co-cultures were fixed after 24 h to assess attachment stage (data not reported here). (**C**) Representation of fresh blastocyst attachment data comparing embryos graded as unhatched or hatching at the start of co-culture. (**D**) Representation of frozen blastocyst attachment data comparing embryos graded as unhatched or hatching at the start of co-culture. (**E**) Day 6 human blastocysts from current IVF cycles (fresh) were artificially hatched from the zona pellucida using acid Tyrode's solution prior to co-culture with Ishikawa for 48 h. Attachment was assessed after 24 h (attached or not attached). At 48 h, co-cultures were fixed with PFA and blastocysts that remained attached after fixation were scored as stably attached, whereas those that became detached during fixation were scored as weakly attached. Attachment of two co-cultures was not assessed at 24 h.](hoz033f3){#f3}

Hatching from the ZP is required for implantation ([@ref39], [@ref45]). All blastocysts were unhatched or were in the process of hatching from the ZP upon transfer to Ishikawa cells. Since the blastocyst could not be reoriented to reveal TE herniation, it was not possible to record accurately hatching status during co-culture. Hatching at the onset of co-culture was therefore correlated with attachment and was found to be a strong indicator of attachment at 24 h among frozen embryos, but not fresh: 9/9 hatching frozen blastocysts attached compared with 1/7 hatching fresh blastocysts (*P* = 0.0004) ([Fig. 3C and D](#f3){ref-type="fig"}). However, 6/10 (60.0%) fresh blastocysts that were unhatched at the beginning of co-culture were attached after 24 h, and by 48 h, the only stably attached fresh blastocyst was one which was unhatched at the start of co-culture ([Fig. 3C](#f3){ref-type="fig"}). We found that 3/8 (37.5%) frozen blastocysts unhatched at the onset of co-culture were stably attached after 48 h ([Fig. 3D](#f3){ref-type="fig"}), but notably, all blastocysts (fresh and frozen) scored as stably attached after 48 h were at least partially hatched by this time; 6/9 (66.7%) had an associated ZP which was lost upon fixation, while the remainder had fully hatched before fixation.

These observations suggest that attachment at 24 h of blastocysts that were unhatched as co-culture began may reflect adherent interactions mediated by the ZP, however, scoring attachment as stable at 48 h is the reflective of robust TE-Ishikawa adherence. To eliminate the confounding factor of hatching status, a series of fresh blastocysts was chemically hatched prior to co-culture. Remarkably, 18/19 (94.7%) were attached after 24 h, and after 48 h, all had attached, with 5/21 (23.8%) achieving weak attachment and 16/21 (76.2%) reaching stable attachment ([Fig. 3E](#f3){ref-type="fig"}).

Fresh, frozen, and artificially hatched fresh cohorts were compared to determine whether embryo quality underpinned the differences in attachment. The proportion of embryos that were of overall high grade on days 3, 5 and 6 did not differ between the cohorts ([Table I](#TB1){ref-type="table"}). Individual grades for expansion or ICM on day 6 also did not differ; however, TE grades were significantly higher in frozen when compared with fresh or artificially hatched fresh cohorts (*P* = 0.00008 and 0.0009, respectively) ([Table I](#TB1){ref-type="table"}). Therefore, TE grade was positively associated with the attachment of partially exposed TE in hatching blastocysts, whereas full TE exposure in artificially hatched embryos led to the attachment of blastocysts regardless of TE grade.

###### 

**Characteristics of human embryos from the experiments presented in** [**Fig. 3**](#f3){ref-type="fig"}.

                               **Fresh embryos (n = 14)**                   **Frozen embryos (n = 15)**                                                                     **Artificially hatched fresh embryos (n = 21)**
  ---------------------------- -------------------------------------------- ----------------------------------------------------------------------------------------------- -------------------------------------------------
  High overall grade day 3     6                                            8                                                                                               8
  High overall grade day 5     1                                            1[^\*^](#tblfn1){ref-type="table-fn"}                                                           0
  High overall grade day 6     1                                            4                                                                                               2
  High expansion grade day 6   13                                           15                                                                                              13
  High ICM grade day 6         3                                            5                                                                                               3
  High TE grade day 6          1[^***a***^](#tblfn2){ref-type="table-fn"}   12[^***a***^](#tblfn2){ref-type="table-fn"}^***,***^[^***b***^](#tblfn3){ref-type="table-fn"}   5[^***b***^](#tblfn3){ref-type="table-fn"}

Numbers of embryos from fresh, frozen \[six embryos frozen at pronuclear stage (PN), 11 embryos frozen at day 2\], and artificially hatched fresh cohorts with high grades. High grades are based on the eligibility/requirement for embryo freezing ([@ref22], [@ref5]). *P* \< 0.05, repeated Chi-squared analysis with a Bonferroni correction.

^\*^Eight out of the 15 frozen embryos were graded on day 5.

^***a***^significant difference between fresh and frozen cohorts.

^***b***^significant difference between frozen and chemically hatched fresh cohorts.

Effects of HA-containing medium on human blastocyst attachment to Ishikawa cells {#sec11}
--------------------------------------------------------------------------------

To test the effect of EmbryoGlue® on blastocyst attachment in our *in vitro* model, we artificially hatched blastocysts prior to treatment and monitored attachment at early timepoints, including 1, 2, 4 and 6 h, as well as 24 and 48 h. Control blastocysts (*n* = 20) were hatched and incubated in GTL, while treated blastocysts (*n* = 23) were hatched and incubated in EmbryoGlue®, before co-culture. There were no differences in blastocyst grade between the two groups ([Table II](#TB2){ref-type="table"}). Rapid attachment of control blastocysts was observed, with 25, 35, 60 and 75% achieving attachment at 1, 2, 4 and 6 h, respectively ([Fig. 4](#f4){ref-type="fig"}). EmbryoGlue®-treated blastocysts tended to exhibit slower kinetics of attachment, although this difference was not significant (43.5 and 47.8% at 4 and 6 h, respectively, [Fig. 4](#f4){ref-type="fig"}). A total of 91.3 and 100% of EmbryoGlue®-treated blastocysts were attached after 24 and 48 h, respectively, compared with 75 and 85% of control blastocysts, respectively, but this difference was not significant ([Fig. 4](#f4){ref-type="fig"}).

###### 

**Characteristics of human embryos from the experiment presented in** [**Fig. 4**](#f4){ref-type="fig"} **, graded on day 6**.

                               **Control (n = 20)**     **EmbryoGlue® (n = 23)**
  ---------------------------- ------------------------ --------------------------
  High overall grade day 6     5 (1 fresh, 4 frozen)    4 (0 fresh, 4 frozen)
  High expansion grade day 6   15 (9 fresh, 6 frozen)   16 (8 fresh, 8 frozen)
  High ICM grade day 6         5 (1 fresh, 4 frozen)    5 (1 fresh, 4 frozen)
  High TE grade day 6          7 (1 fresh, 6 frozen)    13 (5 fresh, 8 frozen)

Control embryos included 10 fresh embryos and 10 frozen: five frozen at PN; two frozen on day 2; and three frozen on day 3. EmbryoGlue®-treated embryos included 12 fresh embryos and 11 frozen: six frozen at PN; one frozen on day 2; and four frozen on day 3. High grades are based on eligibility/requirement for embryo freezing ([@ref22], [@ref5]).

![**Effects of HA-containing medium on human blastocyst attachment to Ishikawa cells.** Fresh blastocysts were treated with control GTL medium or EmbryoGlue® before co-culture with Ishikawa cells and monitoring of attachment over 48 h. Embryo attachment was assessed hourly from 1--6 h, at 24 and 48 h. Percentage of attached embryos is plotted over time of co-culture.](hoz033f4){#f4}

Discussion {#sec12}
==========

Clinical evidence of efficacy has encouraged the use of HA-containing media to increase embryo implantation rates in ART. Blastocyst attachment experiments based on clinical application were performed here to shed much needed light on the activity of HA at implantation. No significant effect of HA on attachment to endometrial epithelial cells *in vitro* was found, although a trend to slower attainment of attachment was observed. These findings reflect recent *in vivo* and *in vitro* animal studies suggesting that instead of promoting blastocyst attachment, HA actually attenuates this aspect of implantation ([@ref38], [@ref9]), implying that HA must affect the implantation potential of human embryos by an alternative mechanism.

To test HA activity at implantation, we extended an existing *in vitro* model of implantation for use with human embryos. This model uses the Ishikawa cell line to provide a well-characterised and consistent *in vitro* endometrial epithelium that allows for the evaluation of blastocyst attachment kinetics ([@ref48]). Recent developments in primary endometrial epithelial organoid culture may yield implantation models that better recapitulate the *in vivo* process ([@ref59]), although the evaluation of attachment processes in a 3D system presents some technical challenges. Here, we used fixation to differentiate between weakly and stably attached embryos and showed that complete hatching from the ZP is not required for stable attachment. Importantly, higher levels of attachment of the higher TE grade frozen embryo cohort suggest that attachment to Ishikawa cells reflects implantation rates *in vivo*, where TE grade appeared superior to ICM and expansion status in predicting implantation ([@ref2]). Artificial hatching prior to co-culture, however, allowed stable attachment of almost all embryos independent of TE grade, underscoring the highly receptive nature of Ishikawa cells. A previous study demonstrated high levels of attachment of hatched day 6 human blastocysts to Ishikawa cells; however, only high grade blastocysts were used ([@ref1]). In addition, our approach revealed that hatched blastocysts attach rapidly to Ishikawa cells, with 75% embryos adhering within 6 h. These findings indicate that herniating high grade TE is capable of mediating attachment, and provide *in vitro* evidence for assisted hatching of low TE grade embryos to enhance implantation potential in the clinical setting.

We characterised the expression of HA-related genes during human pre-implantation development, demonstrating that transcripts for the HA receptors---CD44 and HMMR---but not TLR4, and synthesis (HAS) and degradation (HYAL) enzymes are present in cleavage stage embryos and in both ICM and TE of the blastocyst. HA-containing medium could therefore stimulate CD44 and HMMR during cleavage stage transfer and lead to responses which may improve the implantation potential of the resulting blastocyst. Degradation of HA into active signalling forms by cleavage stage embryos is also possible through HYAL, and this may contribute to HA-containing medium activity during cleavage-stage transfer. As Ishikawa cells express CD44 at the apical domain ([@ref9]), HA could act as an adhesion factor by bridging CD44 receptors present in the apposing TE-Ishikawa membranes. Moreover, increased CD44 expression was noted in blastocysts that adhered more quickly to Ishikawa cells, ([@ref1]). The microarray data also suggest that the human embryo is capable of both synthesising HA and degrading high Mr HA, consistent with murine, ovine and bovine studies ([@ref26]). HAS2, the isoform which synthesises high Mr HA, was not expressed in later stage human embryos, similar to the pattern seen in bovine (Marei *et al*. 2013). However, HYAL1 and HYAL2 were expressed throughout development and in both ICM and TE. These data are consistent with the model that later stage pre-implantation embryos develop in a predominantly low Mr HA environment and, moreover, that embryos are capable of degrading exogenous high Mr HA added to medium into low Mr forms which can be active as trophic signalling agents ([@ref26]).

EmbryoGlue® treatment of day 6 blastocysts had no significant effect on attachment to Ishikawa cells, although there was a trend towards impaired initial attachment that fits with our recent description of enhanced kinetics of mouse blastocyst attachment after hyaluronidase treatment ([@ref9]). EmbryoGlue® was added to the co-culture with blastocysts, mimicking clinical treatment, leading to a final concentration of 0.6%. As EmbryoGlue® is more viscous than co-culture medium ([@ref47]), a bolus of HA may be retained for some time around the blastocyst. High HA concentrations around the blastocyst may stimulate CD44 and HMMR receptors in Ishikawa cells ([@ref57], [@ref9]), which could affect Ishikawa-blastocyst interactions. *In vivo* studies in sheep also highlighted inhibitory effects of HA on implantation ([@ref38]). HA may therefore act like mucins, glycoproteins downregulated from the endometrial epithelial surface at implantation, to allow TE attachment ([@ref3], [@ref40], [@ref23]). We conclude that HA in EmbryoGlue® is not acting here as a CD44 bridging molecule in the initial stages of embryo attachment. This may be attributable to the use of poor quality human embryos, or to the fact that Ishikawa cells are highly receptive to human embryos, to a level that is not sensitive to exogenous HA.

It is unknown which Mr species of HA are present in commercially available media as manufacturers are not obliged under current legislation to disclose the full composition of media to clinics and researchers, although there have been recent calls from professional bodies in ART for this to be reconsidered ([@ref56]). It is likely that EmbryoGlue® contains high Mr HA; however, human embryos also express hyaluronidase enzymes, such as HYAL2, and these may be released into culture medium and effect the breakdown of added high Mr HA into smaller species with trophic signalling capacity. HA may therefore enhance implantation through the signalling downstream of the receptors we found to be expressed in the cleavage and blastocyst stage. MMP9, a member of the matrix metalloproteinase family, has been identified as a downstream target of CD44 ([@ref41]) and implicated in implantation in a number of species ([@ref64], [@ref6]). MMP9 functions in murine and human trophoblast invasion ([@ref18], [@ref46], [@ref63]), and dysregulated expression of MMP9 has been implicated in infertility and early pregnancy loss ([@ref53]). Thus, a mechanism whereby high levels of HA in EmbryoGlue® act to upregulate embryonic genes in preparation for implantation and trophoblast invasion could be envisaged.

In conclusion, we have characterised an *in vitro* model of human embryo attachment and shown that HA may not act as an implantation 'glue', at least with respect to the initial interaction with endometrial epithelium. Our study highlights the difficulties in uncovering basic mechanisms underlying clinical data in ART. Improvements in ART success rates are urgently required, with the development of an implantation-competent embryo and successful initiation of implantation being key bottlenecks. Although much clinical research has taken place into improving ART, the basic scientific understanding is lagging behind. This represents a critical gap in knowledge as the evidence base for treatments in ART and associated risks, and in particular, the use of 'add-ons' to IVF treatment (including HA-containing medium) is a highly controversial area ([@ref55], [@ref61], [@ref36], Wilkinson *et al*. unpublished work, <https://www.hfea.gov.uk/treatments/explore-all-treatments/treatment-add-ons/>). We believe that ART treatments require as strong an evidence base as possible (Stocking *et al*. 2019). We further suggest that an increase in transparency in ART is required; in the case of culture medium, it is important that the full composition of media be disclosed in order to facilitate basic research and allow full understanding of clinical treatments ([@ref10], [@ref56]).
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